Mr. Max Schwartz reports

ORGANIGRAM TO REPORT FOURTH QUARTER FISCAL 2025 RESULTS ON DECEMBER 16, 2025

Organigram Global Inc. will release earnings results for its fourth quarter fiscal 2025 ended Sept. 30, 2025, on Tuesday, Dec. 16, 2025, prior to market open.

The company will host a conference call to discuss its results with details as follows.

Date:  Tuesday, Dec. 16, 2025

Time:  8 a.m. Eastern Time

To ensure you are connected for the full call, the company suggests registering on-line a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through e-mail, including dial-in details and unique conference call codes for entry. Registration is open through the live call.

Participants will receive webcast details by e-mail.

A replay of the webcast will be available within 24 hours after the conclusion of the call on the company's website and will be archived for a period of 90 days following the call.

About Organigram Global Inc.

Organigram is a Nasdaq Global Select Market- and Toronto Stock Exchange-listed company whose wholly owned subsidiaries include Organigram Inc., a licensed cultivator and processor. Through its recent acquisition of Collective Project Ltd., Organigram Global participates in the U.S. and Canadian cannabinoid beverage markets.

Organigram Global is focused on producing high-quality cannabis for adult recreational consumers as well as developing international business partnerships to extend the company's global footprint. Organigram Global has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, Shred, Shred'ems, Monjour, Tremblant Cannabis, Trailblazer, Boxhot, Debunk and Collective Project. Organigram Global operates facilities in Moncton, N.B., and Lac-Superieur, Que., with a dedicated edibles manufacturing facility in Winnipeg, Man. The company also operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities and is optimized for formulation refinement, postprocessing of minor cannabinoids and preroll production. The facility in London will be optimized for labelling, packaging and national fulfilment. The company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

We seek Safe Harbor.